Amgen CEO on New Products, M&A, Drug Pricing Legislation

The transcript discusses Amgen's new state-of-the-art facility in Rhode Island, highlighting its efficiency and sustainability. It covers Amgen's investment strategies amid economic challenges, focusing on biomanufacturing and drug pricing. The pipeline section introduces new medicines like Luma Crass and Ted Spire, addressing unmet medical needs. Amgen's M&A strategy is explored, emphasizing innovation and external development. The impact of new legislation on drug pricing and innovation is discussed, along with the secondary healthcare crisis caused by the pandemic, affecting patient care and diagnosis.

How does Amgen's approach to mergers and acquisitions reflect its business strategy?

Explain the importance of addressing out-of-pocket costs for patients as mentioned in the text.

What strategies does Amgen plan to adopt in response to the current healthcare landscape?

What role does innovation play in Amgen's strategy for the future?